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Synthetic rat atria1 natriuretic factor (Be-ANF-26) stimulated cyclic GMP formation by up to several 
hundred-fold in osteoblast-rich cultures from newborn rat calvaria and in clonal osteogenic sarcoma cells 
(UMR 106-01) which are phenotypically osteoblast. ANF had no effect on the cyclic AMP response to 
parathyroid hormone in the same cells. Specific, high-affinity binding sites for ANF were identified in both 
cell types, with Kd and receptor numbers in normal osteoblasts of 1.2 f 0.1 x lo-i0 M and 42 + 4 x 
lo3 per cell, and in UMR 106-01 cells of 1.4 + 0.1 x lo-i0 M and 22 f 4 x lo3 per cell. 
Atrial natriuretic factor cyclic GMP Osteoblast 
1. INTRODUCTION 
Atria1 natriuretic factor (ANF) is a potent pep- 
tide hormone made in the cells of the cardiac 
atrium, stored there in granules, and acting upon 
vascular smooth muscle and other targets to in- 
fluence vascular tone and fluid and electrolyte 
balance [l-3]. ANF actions include inhibition of 
hormone-stimulated aldosterone secretion [4], 
direct effects on the kidney to promote sodium and 
other electrolyte excretion [1,5], and inhibition of 
vasopressin release [6]. The major vascular effect 
of vasodilatation and lowering of blood pressure 
results from the ability to relax vascular smooth 
muscle directly [7] and to suppress elevated plasma 
renin levels [8]. 
ANF treatment results in a substantial increase 
in cyclic GMP production in several target cells in 
which this has been investigated [9-151. The 
nature of the response suggests that this effect is 
mediated through a cell surface receptor, and 
specific receptors have been identified in rat aortic 
smooth muscle cells [9] in aortic and renal mem- 
branes [9,16], and in adrenal glomerulosa mem- 
branes [17]. In pituitary cells ANF increases cyclic 
GMP production by several hundred-fold [15]. 
Although this was originally suggested to be 
associated with inhibition of CRF-stimulated 
adenylate cyclase and ACTH secretion in those 
cells [ 181, this has not been confirmed in a recent 
careful study [15]. Thus the significance of ANF 
action upon anterior pituitary cells remains 
unknown. 
The present work identifies specific binding sites 
of high affinity for ANF in normal and malignant 
osteoblasts, and a major effect of the hormone on 
cyclic GMP formation in these cells. The 
magnitude and specificity of this response suggests 
that the hormone is likely to have effects on func- 
tions of these cells. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Osteoblast-rich cultures were prepared from 
newborn rat calvaria using methods described in 
detail in [19]. In the late digests after collagenase 
treatment of rat calvaria, osteoblast-rich cultures 
were chosen as rich in alkaline phosphatase and 
parathyroid hormone (PTH)-responsive adenylate 
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cyclase. UMR 106-01 cells are clonal osteogenic 
sarcoma cells which are phenotypically osteoblast . 
The line is a subclone of the UMR 106 line [20] and 
its properties have been reported [21]. Cells were 
cultured as previously described [20,21] in 5% fetal 
calf serum and Eagle’s minimal essential medium 
(MEM). 
2.2. Cyclic nucleotide responses 
Cyclic nucleotide responses to hormones were 
measured in cells growing as replicates in 1Zplace 
multiwell dishes (Costar). At or near confluence 
(0.4 to 0.8 x 106/well), cells were washed and 
medium replaced with 0.5 ml Eagle’s MEM con- 
taining 0.1% bovine serum albumin and 1 mM 
isobutylmethylxanthine (IBMX). After 20 min at 
37°C hormones or carriers were added as in- 
dicated and incubations continued for a further 
10 min or otherwise as shown. Reactions were 
stopped by aspirating media, washing once with 
cold phosphate-buffered saline (PBS), and adding 
1 ml of 95% ethanol-HCl, pH 3.0, at 4°C [12]. 
After 4-6 h the ethanol was removed, and the ex- 
tracts were dried under NZ and reconstituted in 
cyclic GMP or cyclic AMP assay buffer. Samples 
were acetylated before radioimmunoassay as 
described [22]. [1251]Iodotyrosine methyl esters of 
succinylated cyclic GMP and cyclic AMP were 
purchased from the Radiochemical Center, Amer- 
sham, England. Antisera to cyclic GMP and cyclic 
AMP were kindly provided by Dr N.H. Hunt 
(Canberra, Australia); their cross-reactivities have 
been reported [23]. 
2.3. Binding studies 
12’I-ANF was prepared free of unlabelled pep- 
tide as follows. 1 mCi Na12’I was added to 20~1 
ANF (20/1g) in 250~1 phosphate buffer, pH 7.4. 
Chloramine T (5Opg) was added in 100~1 of the 
same buffer, the contents mixed for 10 s, followed 
by addition of Na metabisulphite (50 pg in 100 ,ul). 
Purification was carried out on a Sephadex C25 
(1 x 12 cm) column in a gradient of Na carbonate, 
pH 9.8 (50 ml of 5 mM to 50 ml of 200 mM). 
Mono[“‘I]iodo-ANF (600 pCi/,ug) elutes as a 
peak before the peak of unlabelled ANF. Binding 
of radiolabelled ANF to intact cells was studied 
with confluent replicate cultures growing in 
12-place multiwell dishes. Medium was removed 
from cultured cells and replaced with 0.4 ml 
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Eagle’s MEM containing 0.1% bovine serum 
albumin at 22°C. “‘I-ANF was added in 50~1 of 
the same medium (30-50000 cpm), followed by 
50~1 with or without increasing amounts of 
unlabelled ANF or other test substances. After in- 
cubation at 22°C for 60 min or otherwise as in- 
dicated, medium was rapidly aspirated, cells 
washed twice with excess cold PBS, and the cell 
layers removed in 0.5 ml of 0.5 M NaOH for 
counting in a Packard automatic gamma counter 
with 70% efficiency for 1251. Kinetic calculations 
were based on Scatchard analysis. 
2.4. Hormones and chemicals 
Fetal calf serum was purchased from Flow 
Laboratories, Australasia, and culture media from 
Medos Company, Australia. IBMX was obtained 
from Aldrich Chemical, Milwaukee, WI, USA. 
Synthetic rat atria1 natriuretic factor (Ile-ANF-26) 
was kindly provided by Dr D.F. Veber, Merck, 
Sharp and Dohme, West Point, Philadelphia, 
USA. Synthetic human PTH(l-34) was obtained 
from Beckman (Palo Alto, CA), synthetic salmon 
calcitonin (SCT) was a gift from Dr R.C. 
Orlowski, Armour Pharmaceutical, Kankakee, IL, 
USA. Synthetic rat calcitonin gene-related peptide 
(CGRP) was purchased from Bachem (Torrance, 
CA, USA). 
3. RESULTS 
3. I. Effects of ANF on cyclic nucleotide 
production 
In osteoblast-rich calvarial cells, ANF treatment 
resulted in a 200-fold increase in cyclic GMP pro- 
duction, whereas no effect was obtained with 
PTH, SCT or rat CGRP (table 1). ANF had no ef- 
fect on cyclic AMP formation, which was in- 
creased 30-fold by PTH, as expected, and 4-fold 
by CGRP. This effect of the latter hormone in 
osteoblast-like cells is being investigated further. 
Although the calvarial cultures are osteoblast-rich, 
they clearly are heterogeneous, representing 
osteoblasts at different stages of function, as well 
as containing other, non-osteoblast cells [19]. For 
that reason experiments were carried out in clonal 
osteogenic sarcoma cells which are phenotypically 
osteoblast. In UMR 106-01 cells ANF was the only 
treatment of those tested which increased cyclic 
GMP formation, and a specific response several 
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TabIe 1 
Cyclic AMP and cyclic GMP responses to PTH, rat 
CGRP and ANF in osteoblast-rich calvarial cells 
Cyclic AMP Cyclic GMP 
(pmol/106 cells) (fmol/106 cells) 
Basal 7.5 f 0.6 14.0 + 1.0 
PTH (1O-8 M) 241 + 24 14.0 Y!z 0.9 
rCGRP (3 x lo-* M) 26.0 -I 2.3 13.2 + 1.1 
ANF (3 x lo-’ M) 6.7 f 0.8 945 + 168 
Replicate cultures (0.6 x 10’ cells/well) were treated as 
described in section 2. Means + SE of triplicates 
Table 2 
Cyclic AMP and cyclic GNP responses to ANF, PTH 
and forskolin in UMR 106-01 cells 
Cyclic AMP Cyclic GMP 
(pmol/106 cells) (fmoi/106 cells) 
Basal 
ANF 
2.6 + 0.4 20.9 f 4.5 
(2.3 x lo-’ M) 2.1 rt 0.1 18841 k 3672 
PTH (lo-’ M) 235 + 27 64.6 f 35 
PTH + ANF 253 f 29 27101 it; 1836 
Forskolin (10e6 M) 53.1 * 1.4 25.8 f 4.3 
Forskolin + ANF 53.3 * 4.0 32706 & 4537 
Replicate cultures (0.75 x lo6 cells/well) were treated as 
described in section 2. Means f SE of triplicates 
hundred-fold in magnitude was obtained (table 2). 
Since it has been proposed that ANF inhibits cyclic 
AMP response to hormones in some target cells 
[ 181, this possibility was tested in the clonal 
osteogenic sarcoma cells using PTH as a cyclic 
AMP stimulus. No evidence was obtained for any 
effect of ANF on cyclic AMP responses to PTH in 
repeated experiments (table 2). The cyclic GMP 
response to ANF in UMR 106-01 cells was dose- 
dependent (fig. 1) with half-maximum effectiveness 
obtained at OS-3 x 10e9 M in repeated ex- 
periments. A similar dose relationship occurred 
with osteoblast-rich calvarial cells (not shown). 
3.2. ANF ~~~d~~g to intacf cells 
‘251-labelled ANF bound specifically to both 
normal osteoblast-rich cultures and clonal malig- 
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Fig. 1. Effect of ANF on cyclic GMP formation in UMR 
106-01 cells. Details in section 2. Points are means & SE 
of triplicate measurements. 
reaching a maximum after 50 min at 22°C (not 
shown), and no competition for binding was ex- 
erted by any of the following substances at concen- 
trations of up to 1 pg/ml: PTH, SCT, rat CGRP, 
insulin, mouse epidermal growth factor, human 
transforming growth factor cy, and human tumour 
necrosis factor cy. Although established binding 
was found to be only poorly reversible (not 
shown), Scatchard analyses were carried out to ob- 
tain approximations of kinetic data. For 
osteoblast-rich cells the mean & in three ex- 
periments was 1.2 + 0.1 x lo-” M and receptor 
number 42 +: 4 x lo3 per cell. For UMR 106-01 
cells & values were 1.4 f 0.1 x 10-*” M and recep- 
tor number 22 f 4 x lo3 per cell. 
4. DISCUSSION 
A new target cell response system is reported for 
ANF, in which osteoblast-like cells derived from 
newborn rat bones and from a characterized 
osteogenic sarcoma line have been found to show 
specific and substantial increases in cyclic GMP. 
Demonstration of this effect in calvarial osteoblast 
cultures alone would not be convincing evidence of 
an ANF effect on osteoblasts, since those cultures 
are heterogeneous. However, the finding in the 
clonal osteogenic sarcoma cells strongly suggests 
that some cells of the osteoblast series are a target 
for ANF action. The nature of ANF effect is 
obscure beyond the generation of cyclic GMP, but 
in the present experiments we have been able to 
demonstrate no effect on hormone-responsive 
cyclic AMP formation. Following the initial 
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Fig.2. Specific binding of %ANF to intact caharial osteobIasts (a) and to intact UMR 106-01 cells (b). Insets: 
Scatchard analysis of data. Details in section 2. (a) 25 fmol 12’I-ANF and 5 x lo5 cells per incubation; (b) 20 fmol “‘I- 
ANF and 6 x 10’ cells per incubation. 
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demonstration that ANF inhibited hormone- 
responsive adenylate cyclase in pituitary cells [18] 
there have been no further data to support this 
H51. 
ANF is the most effective known hormonal pro- 
moter of cyclic GMP formation in cells. The in- 
crease in cyclic GMP formation in vascular smooth 
muscle cells [9,12] is probably related to the relax- 
ant action of ANF on those cells, and implies a 
mediatory role for cyclic GMP in vascular smooth 
muscle relaxation, perhaps more important than 
that of cyclic AMP [ 121. Generally, however, there 
is little available information on the intracellular 
effects of elevated cyclic GMP and cyclic GMP- 
dependent phosphorylation [24]. Especially in 
bone there is no hint of what role cyclic GMP 
might have. Early experiments with bone cell mem- 
branes [25] and with osteogenic sarcoma cells [26] 
failed to uncover any stimulus to elevated cyclic 
GMP formation. The present observation points 
to the possibility that cyclic GMP might mediate 
some specific function(s) of osteoblasts, especially 
since such a very large increase in cyclic GMP for- 
mation follows ANF treatment. It also indicates 
that ANF effects might be more pleiotropic than 
previously supposed, and we should seek a func- 
tion for the hormone in bone metabolism. 
Although bone is a substantial store of sodium 
it should not be assumed that ANF effects on bone 
cells resemble those in, for example, renal cells. By 
analogy with cyclic AMP, the nature of the cyclic 
GMP effect could be determined by the differen- 
tiated properties of the osteoblast arget. Thus it 
will be important to determine what are the 
substrates for cyclic GMP-dependent protein 
phosphorylation in osteoblasts, and what effects 
ANF has on major processes in bone, such as bone 
formation, bone resorption, and the coupling be- 
tween the two. 
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